Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML
Blood Podcast
00:00
The Safety and Effectiveness of PD-1 Blockade for Hodgkin Lymphoma
Treatment with concurrent pembrolysumab and AVD shows promising safety and efficacy, but may yield spurious PET findings in some patients. Clerants of CTDNA after cycle 2 was associated with superior progression-free survival. None of the four patients who had persistent disease according to PET at the end of treatment, but negative CTDNA, have relapsed to date.
Play episode from 05:15
Transcript
